Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Stock Information for Processa Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.